STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7
Clinical trials for STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7 explained in plain language.
Never miss a new study
Get alerted when new STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7 trials appear
Sign up with your email to follow new studies for STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy zaps spine tumors before they paralyze
Disease control OngoingThis study tests a combination of two treatments—heat-based tumor destruction (thermal ablation) and precise high-dose radiation (stereotactic radiosurgery)—for people whose cancer has spread to the spine and is pressing on the spinal cord. The goal is to control the tumor and pr…
Matched conditions: STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 03:17 UTC
-
New combo tackles Drug-Resistant lung cancer
Disease control OngoingThis early-stage trial tests a combination of two drugs, sapanisertib and osimertinib, in people with advanced EGFR-mutant non-small cell lung cancer that has worsened after previous treatment. The main goal is to find the safest dose and check for side effects. About 36 particip…
Matched conditions: STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 03:17 UTC
-
New combo therapy aims to shrink metastatic tumors in lung and colon cancer
Disease control OngoingThis study tests two immunotherapy drugs, durvalumab and tremelimumab, alone or combined with low or high-dose radiation, in people with metastatic colorectal or non-small cell lung cancer. The goal is to see if adding radiation helps the drugs work better to shrink tumors. About…
Matched conditions: STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New combo therapy shows promise for tough lung cancer
Disease control OngoingThis study tests two drugs, erlotinib and cabozantinib, given alone or together in people with advanced non-small cell lung cancer that has not responded to earlier treatments. The goal is to see if the combination works better than either drug alone at slowing cancer growth. Abo…
Matched conditions: STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
New drug combo shows promise for Tough-to-Treat lung cancer
Disease control OngoingThis study tests whether combining two drugs, trametinib and docetaxel, can shrink tumors in people with a specific genetic form of advanced lung cancer (KRAS mutation). The trial includes 60 patients whose cancer has worsened after one or two prior treatments. The main goal is t…
Matched conditions: STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase study tests the safety and best dose of combining two drugs, ceritinib and everolimus, in people with advanced solid tumors or a specific type of lung cancer (ALK-positive NSCLC). The goal is to find the highest dose that is safe and to see if the combination can…
Matched conditions: STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:39 UTC
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control OngoingThis study tests a combination of two drugs, cediranib and olaparib, in people with advanced or inoperable solid tumors, including certain breast, lung, and pancreatic cancers. The goal is to see if the combo can shrink tumors or slow their growth by blocking enzymes that cancer …
Matched conditions: STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 08, 2026 12:04 UTC